ANA M. MARIN SANCHEZ

Dr. ANA M. MARIN SANCHEZ

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2018 in Expert Review of Clinical Immunology
Verified
Journal Article
Closed access
ASAlbert Selva-O'Callaghan
Albert Selva-O'Callaghan
MAMarcelo Alvarado-Cardenas
Marcelo Alvarado-Cardenas
IPIago Pinal-Fernández
Iago Pinal-Fernández
ETErnesto Trallero-Araguás
Ernesto Trallero-Araguás
JMJosé Cesar Milisenda
José Cesar Milisenda
JGJosep María Grau-Junyent
Josep María Grau-Junyent
Introduction: Musculoskeletal manifestations are well-recognized side effects of treatment with statins. New advances in this field have appeared in recent years. This review focuses on the diagnosis of these conditions and their underlying pathogenesis, in particular immune-mediated necrotizing myopathy. Areas covered: Clinical phenotypes including rhabdomyolysis, myalgia and/or mild hyperCKemia, self-limited toxin statin myopathy, and immune-mediated necrotizing myopathy are herein described. Therapeutic recommendations and a diagnostic algorithm in statin-associated myopathy are also proposed. The etiology and pathogenesis of statin-induced myopathy has mainly focused on the anti-HMGCR antibodies and the responsibility of the immune-mediated necrotizing myopathy is discussed. The fact that patients who have not been exposed to statins may develop statin-associated autoimmune myopathy with anti-HMGCR antibodies is also addressed. The literature search strategy included terms identified by searches of PubMed between 1969 and December 2017. The search terms ‘myositis’, ‘statin-induced autoimmune myopathy’, ‘immune-mediate necrotizing myopathy’, ‘statins’, ‘muscular manifestations’, and ‘anti-HMGCR antibodies’ were used. Expert commentary: Full characterization of the known phenotypes of statin toxicity and the specific role of the anti-HMGCR in those exposed and not exposed (i.e. juvenile forms) to statins and in some types of neoplasms is of paramount relevance.

15 October 2014 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MGMireia Giménez-Barcons
Mireia Giménez-Barcons
ACAnna Casteràs
Anna Casteràs
MAMaria del Pilar Armengol
Maria del Pilar Armengol
EPEduard Porta-Pardo
Eduard Porta-Pardo
PCPaula A Correa
Paula A Correa
RCRoger Colobran
Roger Colobran
Down syndrome (DS), or trisomy of chromosome 21, is the most common genetic disorder associated with autoimmune diseases. Autoimmune regulator protein (AIRE), a transcription factor located on chromosome 21, plays a crucial role in autoimmunity by regulating promiscuous gene expression (pGE). To investigate if autoimmunity in DS is promoted by the reduction of pGE owing to dysregulation of AIRE, we assessed the expression of AIRE and of several peripheral tissue-restricted Ag genes by quantitative PCR in thymus samples from 19 DS subjects and 21 euploid controls. Strikingly, despite the 21 trisomy, AIRE expression was significantly reduced by 2-fold in DS thymuses compared with controls, which was also confirmed by fluorescent microscopy. Allele-specific quantification of intrathymic AIRE showed that despite its lower expression, the three copies are expressed. More importantly, decreased expression of AIRE was accompanied by a reduction of pGE because expression of tissue-restricted Ags, CHRNA1, GAD1, PLP1, KLK3, SAG, TG, and TSHR, was reduced. Of interest, thyroid dysfunction (10 cases of hypothyroidism and 1 of Graves disease) developed in 11 of 19 (57.9%) of the DS individuals and in none of the 21 controls. The thymuses of these DS individuals contained significantly lower levels of AIRE and thyroglobulin, to which tolerance is typically lost in autoimmune thyroiditis leading to hypothyroidism. Our findings provide strong evidence for the fundamental role of AIRE and pGE, namely, central tolerance, in the predisposition to autoimmunity of DS individuals.

1 September 2019 in Journal of Autoimmunity
Verified
Journal Article
Closed access
DÁDaniel Álvarez-Sierra
Daniel Álvarez-Sierra
ASANA M. MARIN SANCHEZ
ANA M. MARIN SANCHEZ
PRPaloma Ruiz-Blázquez
Paloma Ruiz-Blázquez
Carmen de Jesús GilCarmen de Jesús Gil
Carmen de Jesús Gil
CICarmela Iglesias-Felip
Carmela Iglesias-Felip
RPRicardo Pujol-Borrell
Ricardo Pujol-Borrell

1 May 2017 in Autoimmunity Reviews
Verified
Journal Article
Closed access
DBDavid Bernal-Bello
David Bernal-Bello
JTJaime Garcia De Tena
Jaime Garcia De Tena
AGAlfredo Guillen-Del-Castillo
Alfredo Guillen-Del-Castillo
ASAlbert Selva-O'Callaghan
Albert Selva-O'Callaghan
ECEduardo L. Callejas-Moraga
Eduardo L. Callejas-Moraga
CSCarmen Pilar Simeón-Aznar
Carmen Pilar Simeón-Aznar

15 May 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IPIrma Pujol-Autonell
Irma Pujol-Autonell
RARosa-Maria Ampudia
Rosa-Maria Ampudia
RPRaquel Planas
Raquel Planas
SMSilvia Marin-Gallen
Silvia Marin-Gallen
JCJorge Carrascal
Jorge Carrascal
MVMarta Vives-Pi
Marta Vives-Pi
Introduction Efferocytosis is a crucial process by which apoptotic cells are cleared by phagocytes, maintaining immune tolerance to self in the absence of inflammation. Peripheral tolerance, lost in autoimmune processes, may be restored by the administration of autologous dendritic cells loaded with islet apoptotic cells in experimental type 1 diabetes. Objective To evaluate tolerogenic properties in dendritic cells induced by the clearance of apoptotic islet cells, thus explaining the re-establishment of tolerance in a context of autoimmunity. Methods Bone marrow derived dendritic cells from non-obese diabetic mice, a model of autoimmune diabetes, were generated and pulsed with islet apoptotic cells. The ability of these cells to induce autologous T cell proliferation and to suppress mature dendritic cell function was assessed, together with cytokine production. Microarray experiments were performed using dendritic cells to identify differentially expressed genes after efferocytosis. Results Molecular and functional changes in dendritic cells after the capture of apoptotic cells were observed. 1) Impaired ability of dendritic cells to stimulate autologous T cell proliferation after the capture of apoptotic cells even after proinflammatory stimuli, with a cytokine profile typical for immature dendritic cells. 2) Suppressive ability of mature dendritic cell function. 3) Microarray-based gene expression profiling of dendritic cells showed differential expression of genes involved in antigen processing and presentation after efferocytosis. 4) Prostaglandin E2 increased production was responsible for immunosuppressive mechanism of dendritic cells after the capture of apoptotic cells. Conclusions The tolerogenic behaviour of dendritic cells after islet cells efferocytosis points to a mechanism of silencing potential autoreactive T cells in the microenvironment of autoimmunity. Our results suggest that dendritic cells may be programmed to induce specific immune tolerance using apoptotic cells; this is a viable strategy for a variety of autoimmune diseases.

11 September 2015 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
RPR. Pujol-Borrell
R. Pujol-Borrell
MGM. Giménez-Barcons
M. Giménez-Barcons
ASANA M. MARIN SANCHEZ
ANA M. MARIN SANCHEZ
RCR. Colobran
R. Colobran
As most autoimmune diseases, inherited predisposition to Graves’ disease (GD) is polygenic with the main contributory genes being located in the HLA region. Also, as in other autoimmune diseases, family linkage, candidate gene association, and GWAS studies have identified an expanding number of predisposing genes (CTLA4, CD40, PTPN22…) and 2 of them, TG and TSHR, are thyroid specific. In spite of this expanding number of associated genes, it has been estimated that all together they account for only a 20% of the heritability of GD. TSHR is of special interest as it codes for the target of TSHR stimulating antibodies (TSAbs), which are unequivocally pathogenic and an exception in autoimmunity by being stimulating rather than neutral, blocking, or cytotoxic. This is surprising because the generation of stimulating TSHR antibodies by immunisation of laboratory animals has been remarkably difficult, suggesting an underlying mechanism that favours stimulating over neutral or blocking anti-TSHR antibodies must be operating in GD patients. Besides, after HLA, TSHR is the gene most tightly associated to GD. The TSHR polymorphisms conferring susceptibility are located in the unusually large intron 1. Two mechanisms have been already put forward to explain its association with GD. According to one, the risk alleles determine an increase in the expression of TSHR mRNA splice variants that code for a soluble form of the receptor. The wider distribution of soluble TSHR would favour its immunogenicity and the development of an autoimmune response to it. It does not explain why it becomes immunogenic, as immunogenicity and distribution are not necessarily connected, nor why the immune response focus to the production of stimulating antibodies. According to the second mechanism proposed, the risk alleles determine a lower TSHR expression in the thymus and this would favour the escape of more TSHR reactive T cells, that is, central tolerance failure. The unexpected finding that thymocytes express TSHR and that TSAbs stimulate them lead to postulate that this would accelerate their egress from the thymus and a less efficient deletion of the TSHR self-reactive T cells. It can be envisaged that these autoreactive T cells may enhance the production of TSHR-Abs in the germinal centres of the thyroid draining lymph nodes, especially of those capable of further stimulating the egress of autoreactive T cells from the thymus. This mechanism, which does not exclude the former, provides and insight of the way in which TSAbs are favoured over neutral or blocking antibodies. Finally this would explain the frequent finding of thymic hyperplasia in GD patients.